Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YXZQL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SGN-15
|
|||||
| Synonyms |
CBR96-Doxorubicin Immunoconjugate; hBR96; BMS-182248; BMS-182248-01; BR96-DOX; BR96-DAPDOX; SGN 15; SGN15
Click to Show/Hide
|
|||||
| Organization |
Seagen Inc.; Bristol Myers Squibb Co.
|
|||||
| Drug Status |
Terminated in phase 2
|
|||||
| Indication |
In total 5 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Terminated in phase 2
Colorectal cancer [ICD11:2B91]
Terminated in phase 2
Non-small cell lung cancer [ICD11:2C25]
Terminated in phase 2
Ovarian cancer [ICD11:2C73]
Terminated in phase 2
Prostate cancer [ICD11:2C82]
Terminated in phase 2
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Anti-Lewis-Y mAb cBR96
|
Antibody Info | ||||
| Antigen Name |
Lewis Y
|
Antigen Info | ||||
| Payload Name |
Doxorubicin
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Puchem SID | ||||||
| Drugbank ID | ||||||
| ChEBI ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.